Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-760 in Combination With R-GemOx in Relapsed/Refractory DLBCL
NCT07409428Phase 3Recruiting
- Sponsor
- HUTCHMED
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing HMPL-760 + R-GemOx with Placebo + R-GemOx (2 arms). Primary endpoints: Progression-Free Survival at 2 years and Overall Survival at 2 years. Started Mar 2026; status: recruiting.
02
Drugs
HMPL-760
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07409428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07409428.